Mr. Love joined Annexon Biosciences as President and Chief Executive Officer in May 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals where he led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales.  He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion in addition to milestones and royalties. Mr. Love is a corporate attorney by training, and prior to joining Elan served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.

 Mr. Love joined Annexon Biosciences as President and Chief Executive Officer in May 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals where he led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales.  He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion in addition to milestones and royalties. Mr. Love is a corporate attorney by training, and prior to joining Elan served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.